Cis-Platinum As Second-line Chemotherapy in Advanced Gastric Adenocarcinoma. A Phase II Study of the EORTC Gastrointestinal Tract Cancer Cooperative Group
Overview
Affiliations
Thirty-four patients with measurable metastatic gastric adenocarcinoma refractory to prior chemotherapy were treated with cis-platinum 100 mg/m2 in a 6-hr infusion at 3-week intervals. Thirty-one patients were evaluable for response. There were three complete and three partial responses. Median duration of response was 4 months. Toxicity consisted mainly of nausea and vomiting and was severe in 12 patients. One patient had a severe but reversible renal failure. These results confirm other data reported in the literature. Cis-platinum has activity in gastric adenocarcinoma and should now be further investigated in first-line chemotherapy.
Chon H, Rha S, Park H, Shin S, Kim H, Roh J Cancer Chemother Pharmacol. 2011; 68(4):991-9.
PMID: 21327684 PMC: 3180611. DOI: 10.1007/s00280-011-1560-9.
Pharmacotherapy for oesophagogastric cancer.
Jackson C, Starling N, Chua Y, Cunningham D Drugs. 2007; 67(17):2539-56.
PMID: 18034590 DOI: 10.2165/00003495-200767170-00006.
Nakayama N, Koizumi W, Tanabe S, Sasaki T, Saigenji K Gastric Cancer. 2006; 9(3):185-91.
PMID: 16952036 DOI: 10.1007/s10120-006-0371-x.
Status of treatment for advanced gastric carcinoma.
Tsai J, Safran H Curr Oncol Rep. 2003; 5(3):210-8.
PMID: 12667418 DOI: 10.1007/s11912-003-0112-9.
Diagnosis and treatment of gastric cancer.
Hendlisz A, Bleiberg H Drugs. 1995; 49(5):711-20.
PMID: 7601012 DOI: 10.2165/00003495-199549050-00006.